SC Launch

  • sam patrick posted an article
    Zylo, Hoth expand relationship see more

    Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has completed a strategic investment in [SC Launch, Inc., Portfolio Company] Zylö Therapeutics, Inc. (“Zylö”).

    Mr. Robb Knie, Chief Executive Officer of Hoth, commented, “We are pleased to expand our partnership with Zylö and look forward to working together as our therapeutic for Lupus patients continues through the next phase of development. This small equity investment in Zylö is a further commitment to our belief in Zylö’s science and team.”

    Stated Scott Pancoast, CEO of Zylö Therapeutics, “Partnering with Hoth in 2019 was an important step in propelling our lupus program forward. This equity investment in Zylö stock represents an expansion of the partnership and is a win-win for the two companies.”

    According to estimates by the Lupus Foundation of America (LFA), 1.5 Million Americans currently suffer from lupus, with 16,000 new cases reported annually. Tragically, lupus strikes mostly women of child-bearing age. Worldwide, the LFA estimates that at least five million people may have some form of the disease. Of the people diagnosed, approximately two-thirds will develop CLE. The annual average cost to provide medical treatment for a person with lupus: $6,000 to $10,000, with some treatment costing several thousand dollars a month.

    ###

    About Zylö Therapeutics, Inc.
    Zylö, dedicated to bringing innovative technologies to multiple facets of medicine, has an innovative sustained-release drug-delivery system that was developed by Joel Friedman MD PhD, Adam Friedman MD FAAD, and Andrew Draganski PhD. The delivery system uses patented xerogel-derived nanoparticles, called Z-pods™, to deliver—in a sustained and controlled manner—notoriously hard-to-deliver therapeutic agents through topical administration. For more information, please visit; http://www.zylotherapeutics.com/

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH’s pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has recently entered into a Joint Development Agreement to further the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH). To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of AEA-loaded Z-pods™, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as “anticipate”, “being”, “will”, “plan”, “may”, “continue”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth’s current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption “Risk Factors” in Hoth’s Form 10K for the period ending December 31, 2018, and Hoth’s other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth’s current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

  • sam patrick posted an article
    SCRA Celebrates $1 Billion in Support of South Carolina Start-Ups see more

    Summerville, S.C.– SCRA, a public, non-profit corporation that fuels South Carolina’s innovation economy, celebrated a milestone of $1 billion of follow-on capital secured by Client Companies in the SC Launch Program. SC Launch, SCRA’s entrepreneurial program, provides mentoring, grants and access to SC Launch, Inc. investments for qualified, South Carolina-based, early-stage companies.

    Access to follow-on capital is critical to the success of entrepreneurial companies. Angel investors, venture capital funds and corporate investors are the main source of follow-on funding secured by SC Launch companies. The $1 billion in follow-on investments were acquired by more than 140 Client Companies over the span of 12 years.

    “Our job, and our passion, is guiding companies to the next stage in the entrepreneurial life cycle and seeing them through to success,” said Bob Quinn, SCRA Executive Director, “The funding provided by SC Launch is vital in enabling our Client Companies to overcome many of the barriers faced by early-stage enterprises. However, void of follow-on funding, these companies often flounder. Therefore, we are thrilled to be celebrating this $1 billion milestone.”

    “Through the SC Launch Program, SCRA helps entrepreneurs to strategically navigate the ups and downs of running a company. We also work alongside entrepreneurs to secure grants, prepare them for investments and secure capital from other sources.” said Jill Sorensen, SCRA Director of Entrepreneurial Programs and Executive Director of SC Launch, Inc. “Our team rolls up our sleeves and dives in to provide an advantage for the entrepreneurs we support.”

    SCRA is a state-chartered organization that fuels job creation and grows South Carolina’s innovation economy. The SC Launch Program is open to qualified South Carolina companies in the Advanced Materials/Manufacturing, Information Technology and Life Sciences sectors.

    ###

    About SCRA
    Chartered in 1983 by the State of South Carolina as a public, non-profit corporation, SCRA fuels South Carolina’s Innovation Economy by supporting entrepreneurs, enabling academic research and its commercialization, and connecting industry to innovators.

  • sam patrick posted an article
    Accessible Diagnostics receives $250,000 SC Launch Investment see more

    March 15, 2018 11:50 AM Eastern Daylight Time

    SUMMERVILLE, S.C.--(BUSINESS WIRE)--SC Launch, Inc., SCRA’s entrepreneurial program, recently finalized a $250,000 investment for Accessible Diagnostics, a life science company based in Greenville, SC. The company was accepted as an SC Launch Client Company in December 2014 and received a $50,000 Acceleration Grant in June 2017.

    Accessible Diagnostics is developing a smartphone-based, at-home health test platform in collaboration with healthcare professionals. Their first proprietary product, Vet-Tab, is a painless glucose test for a beloved family member, a diabetic dog. The investment will be used to finalize product development, manufacture the initial inventory and launch sales. The company has also begun the regulatory process to sell painless human glucose test.

    “Concepts to Companies and accredited individuals provided the seed capital for Accessible Diagnostics to startup and reach this point,” said John Warner, Accessible Diagnostics CEO and Co-Founder. “We are grateful for Acceleration Grant last summer to help with prototype development and their investment this spring to help launch Vet-Tab sales.”

    “Accessible Diagnostics can create enormous value by aggregating data to integrate into other digital heath platforms being created in the market,” said Director of Entrepreneurial Programs and SC Launch Inc. Executive Director, Jill Sorenson. “We are excited to see the growth of the company and the impact to South Carolina.”

    SCRA is a state-chartered organization that fosters job creation and grows South Carolina’s Innovation Economy. The SC Launch program is SCRA’s entrepreneurial platform that provides mentoring, grants and investments to qualified, South Carolina companies in the Advanced Materials/Manufacturing, Information Technology and Life Sciences industries.

    About SCRA

    http://www.scra.org/

    Chartered in 1983 by the State of South Carolina as a public, non-profit corporation, SCRA fosters South Carolina's Innovation Economy by supporting entrepreneurs, enabling academic research and its commercialization, and connecting industry to innovators.

    Contacts

    SCRA
    Jessica Cokins, 843-760-3273
    jessica.cokins@scra.org